OKLAHOMA CITY, March 14, 2019 /PRNewswire-PRWeb/ -- EyeCRO LLC has been awarded full accreditation from AAALAC International
"We are excited to join the select group of AAALAC-accredited institutions. There are approximately 1000 institutions that have achieved this level of excellence worldwide and we are proud to accomplish this within one year after opening our new research facility," said Dr. Eric Phelps, Director of Research and Development.
"Our team is excited to receive this tremendous honor that recognizes our commitment to strong science and the highest standards of preclinical research," said Alexander Quiambao, Vice President of Operations. "This enhances our ability to assist companies around the world which are advancing vision-saving therapies that can treat various forms of blindness," said Quiambao.
EyeCRO has also recently finished construction of a state-of-the-art addition to its facility for conducting good laboratory practice (GLP) preclinical studies. "This addition will allow us to provide services covering the full-range of preclinical ophthalmic drug development, from performing initial proof-of-concept pharmacology studies to conducting important toxicology and pharmacokinetic studies required by the FDA to enable human clinical trials," said Dr. Rafal Farjo, Chief Executive Officer.
About EyeCRO EyeCRO is the global leader in the performance of preclinical ophthalmic research to advance therapeutic discovery and development programs. The company operates laboratories in Oklahoma City, OK and Ann Arbor, MI which provide validated contract research services to the ophthalmic research community worldwide. These include studies in a number of well-established models to accurately evaluate the activity and pharmacokinetics of test agents for treating diseases such as Wet and Dry Age-Related Macular Degeneration, Diabetic Retinopathy, Retinitis Pigmentosa, Leber's Congenital Amaurosis, Glaucoma, Dry Eye Disease, Conjunctivitis, and Uveitis. In addition, the company offers formulation services for eyedrop delivery of lipophilic small molecules using the innovative and patented MiDROPS platform. EyeCRO is currently advancing an internal program utilizing this technology with Cyclosporin-A-MiDROPS for the once-daily treatment of Dry Eye Disease and expects to begin clinical trials by the first quarter of 2020. For more information, see http://www.EyeCRO.com
Subscribe to our Free Newsletters!